ABSTRACT

A simple, precise, accurate, and rapid reverse phase-high performance liquid chromatography (RP-HPLC) based analytical method with UV detection has been developed for the quantification of amlodipine besylate (AML) and celecoxib (CEL) in their fixed dose formulation. The analysis was performed on Thermosil C18 analytical column (250 × 4.6 mm, i.d., 5 µm). The mobile phase consisted of a mixture of 70 volumes of methanol and 30 volumes of 0.1 % ortho-phosphoric acid run in isocratic mode at a flow rate of 1 mL/min. Detection of analytes was carried at 252 nm and with linearity obtained at concentration ranges of 3-18 µg/ml and 75-450 µg/ml for AML and CEL respectively. The retention time of AML and CEL were 2.582 and 3.407 min respectively. The recoveries obtained were 99.46?101.36 % for AML, and 99.96–100.87 % for CEL. The analytical method validation was done in accordance with the guidelines of international conference of harmonization for the parameters with accuracy, precision, specificity, robustness, limits of detection and quantitation. The developed HPLC method was successfully applied in the analysis of commercial available dosage forms containing AML and CEL. Keywords : Amlodipine besylate, Celecoxib, RP-HPLC, Tablet dosage form
Publication date: 01/08/2022

https://ijbpas.com/pdf/2022/August/MS_IJBPAS_2022_6327.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.8.6327